Novo working up a weekly insulin; Zafgen embarks on a rare disease trial;

@FierceBiotech: Hemispherx to test FDA-rejected drug, other candidates against Ebola. FierceBiotech Research story | Follow @FierceBiotech

@JohnCFierce: Baxter inks a big lease in the heart of Cambridge for biopharma R&D headquarters - (more for hubs, less for Chicago). More | Follow @JohnCFierce

@DamianFierce: And now the @FierceMedDev Fierce 15, featuring therapeutic apps, next-gen valves and a light-based hearing aid. Report from FierceMedicalDevices | Follow @DamianFierce

@EmilyMFierce: Global Survey Says We're Eating Better, But Our Diet Is Still Unsustainable. National Geographic story | Follow @EmilyMFierce

> Novo Nordisk ($NVO) and its expansive diabetes R&D operation are in the early stages of development with a once-weekly insulin, a lucrative prospect years away from the market. News

> Zafgen ($ZFGN) has kicked off a Phase III trial of its obesity drug beloranib in Prader-Willi syndrome, a rare genetic disease that results in unrelenting hunger. More

Medical Device News

@FierceMedDev: We've compiled the 15 fiercest med tech companies. Check out FierceMedicalDevices' Fierce 15. Special Report | Follow @FierceMedDev

@MichaelGFierce: RT @EmilyMFierce: Did you miss our list of notable academic-pharma alliances of 2014? Check it out here. Report from FierceBiotechResearch | Follow @MichaelGFierce

@VarunSaxena2: Med tech attorneys say FDA ramping up monitoring of device promotion. Editor's Corner | Follow @VarunSaxena2

@EmilyWFierce: Babies tune out sounds that don't exist in mother's native tongue, form "library of sounds" in brain. Story from Wired | Follow @EmilyWFierce

> Endo to settle remaining claims over vaginal mesh products. Article

> Developer of eye test for Alzheimer's raises $15M in VC round. News

Pharma News

@FiercePharma: Report: Indian government to take legal action over drug quality paper. FiercePharmaManufacturing item | Follow @FiercePharma

@TracyStaton: ICYMI: Who are the fiercest companies in biotech these days? Check out @FierceBiotech's latest Fierce 15. Special Report | Follow @TracyStaton

@CarlyHFierce: Pfizer DTC message: Hey guys, women say it's cool to take Viagra. Story via FiercePharmaMarketing | Follow @CarlyHFierce

> Orphan drugs may be pricey, but payers are barely balking. Article

> FDA slaps Valeant with a warning letter. Will Allergan slap it, too? More

Drug Delivery News

> Projection: Implantable drug delivery market to reach $21.1B by 2018. Item

> Which vehicle works best? High-speed testing gives drug delivery a boost. Story

> Alnylam launches study to support its rare disease candidate ALN-AS1. More

> Allergan's drug-delivering eye implant gets expanded indication from FDA. News

> Detoxified anthrax used to deliver cancer drugs within cells. Article

Diagnostics News

> Thermo Fisher has made universal companion Dx development an official trend. Report

> Autism diagnosis could become clearer with sound/sight response screening. More

> Japan approves Infraredx's intravascular ultrasound Dx imaging device. Article

> Trinity Biotech expects FDA submission in early 2015 for heart failure Dx. Story

> J&J, others join $6.5M funding round for U.K. liquid biopsy company. Item

Pharma Marketing News

> Pfizer DTC message: Hey guys, women say it's cool to take Viagra. Story

> Survey: No need to worry about sky-high prices for orphan drugs. Item

> Sunshine fact: $3.5B + 546,000 docs equals one unwieldy database. Report

> Sucampo's Amitiza targets 45-plus women with belly-as-balloon DTC ads. Article

Suggested Articles

As Relay looks to enter the clinic in 2020, the company is adding a trio of biopharma vets to its leadership team.

A phase 3 trial of Myovant Sciences’ relugolix in prostate cancer has met its primary endpoint, teeing the company up to file for FDA approval.

The Medicines Company, fresh from its turn at the AHA this weekend, has seen its shares jump on growing rumors that Novartis wants to acquire it.